Forte Biosciences
FBRX
Market cap $8.92M

6.11 USD

+0.27

4.62%

At close Nov 18, 4:00 PM EST

1 day

4.62%

5 days

12.73%

1 month

29.18%

3 months

-25.94%

6 months

-59.75%

Year to date

-70.55%

1 year

-49.88%

5 years

-98.55%

10 years

-98.55%

About: Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).

Employees: 11

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1.89% less ownership

Funds ownership: 52.34% [Q2] → 50.45% (-1.89%) [Q3]

30% less funds holding

Funds holding: 33 [Q2] → 23 (-10) [Q3]

60% less capital invested

Capital invested by funds: $10.2M [Q2] → $4.12M (-$6.13M) [Q3]

77% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 13

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 20

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$64

947%

upside

Avg. target

$70

1,037%

upside

High target

$75

1,127%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Chardan Capital Daniil Gataulin 43% 1-year accuracy 13 / 30 met price target	947%upside $64	Buy Maintained	15 Nov 2024
Chardan Capital Daniil Gataulin 43% 1-year accuracy 13 / 30 met price target	1,128%upside $75	Buy Maintained	19 Aug 2024

See Analyst Rankings

Financial journalist opinion

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2024 results and provided a business update. Third Quarter 2024 Business Highlights “We continue to make excellent progress with FB102 and have begun dosing patients in a celiac disease clinical trial. In addition to safety and tolerability, we will be assessing the histological impac.

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards to purchase a total of 70,000 shares of common stock to new non-exec.

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024 results and provided a business update. First Quarter 2024 Business Highlights “Forte continues to make excellent progress with FB102. As we indicated last quarter, the single ascending dose (SAD) portion of the FB102 phase 1 trial was successfully completed. We expect the dosing.

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

Zacks Investment Research

What Makes Forte Biosciences (FBRX) a New Buy Stock

Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Forte Biosciences (FBRX) a New Buy Stock

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update. 2023 Business Highlights “Forte achieved a major milestone by advancing FB-102 into the clinic and beating the timelines we targeted in our third quarter business update. The single ascending dose (SAD) portion of the FB-102 phase 1 trial was success.

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of an equity award to purchase 25,000 shares of common stock to a new non-executive employee as a material inducement to s.

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

See News Rankings

Charts implemented using Lightweight Charts™